Betta Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 3/6
Betta Pharmaceuticals has a total shareholder equity of CN¥5.7B and total debt of CN¥2.3B, which brings its debt-to-equity ratio to 40.6%. Its total assets and total liabilities are CN¥9.4B and CN¥3.6B respectively. Betta Pharmaceuticals's EBIT is CN¥406.6M making its interest coverage ratio 11.2. It has cash and short-term investments of CN¥816.4M.
Key information
40.6%
Debt to equity ratio
CN¥2.32b
Debt
| Interest coverage ratio | 11.2x |
| Cash | CN¥816.38m |
| Equity | CN¥5.73b |
| Total liabilities | CN¥3.63b |
| Total assets | CN¥9.36b |
Recent financial health updates
Does Betta Pharmaceuticals (SZSE:300558) Have A Healthy Balance Sheet?
Nov 26
These 4 Measures Indicate That Betta Pharmaceuticals (SZSE:300558) Is Using Debt Reasonably Well
Jul 05Recent updates
Is Now The Time To Put Betta Pharmaceuticals (SZSE:300558) On Your Watchlist?
Dec 17Does Betta Pharmaceuticals (SZSE:300558) Have A Healthy Balance Sheet?
Nov 26We Think That There Are Some Issues For Betta Pharmaceuticals (SZSE:300558) Beyond Its Promising Earnings
Nov 04Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) P/E Is Still On The Mark Following 29% Share Price Bounce
Sep 30Results: Betta Pharmaceuticals Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates
Aug 07Unpleasant Surprises Could Be In Store For Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) Shares
Jul 30These 4 Measures Indicate That Betta Pharmaceuticals (SZSE:300558) Is Using Debt Reasonably Well
Jul 05Betta Pharmaceuticals' (SZSE:300558) Earnings Are Weaker Than They Seem
Apr 26Earnings Miss: Betta Pharmaceuticals Co., Ltd. Missed EPS By 6.1% And Analysts Are Revising Their Forecasts
Apr 23What Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) P/E Is Not Telling You
Apr 16Financial Position Analysis
Short Term Liabilities: 300558's short term assets (CN¥1.5B) do not cover its short term liabilities (CN¥1.8B).
Long Term Liabilities: 300558's short term assets (CN¥1.5B) do not cover its long term liabilities (CN¥1.9B).
Debt to Equity History and Analysis
Debt Level: 300558's net debt to equity ratio (26.3%) is considered satisfactory.
Reducing Debt: 300558's debt to equity ratio has increased from 26.5% to 40.6% over the past 5 years.
Debt Coverage: 300558's debt is well covered by operating cash flow (51%).
Interest Coverage: 300558's interest payments on its debt are well covered by EBIT (11.2x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 22:51 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Betta Pharmaceuticals Co., Ltd. is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yue Gao | Changjiang Securities Co. LTD. |
| Jin Zhang | China International Capital Corporation Limited |
| Jing Qiang | China International Capital Corporation Limited |